跳至主要内容
临床试验/ACTRN12618001590257
ACTRN12618001590257撤回未知

Gut Microbiome Transfer for the Treatment of Crohn’s Disease

Associate Professor Justin O'Sullivan0 个研究点目标入组 20 人开始时间: 2018年9月25日最近更新:
适应症

试验速览

阶段
未知
状态
撤回
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
20 Years 至 50 Years(—)
性别
Male

入选标准

  • - 20-50 years old
  • - mild to moderate Crohn's disease (HBI 5-16)
  • - 20-50 years old
  • - BMI 18.5 - 24.9 kg/m2

排除标准

  • Donor exclusion criteria:
  • - Chronic disease
  • - Gastrointestinal disease (including irritable bowel syndrome, coeliac and inflammatory bowel disease)
  • - Any transmissible viral, bacterial, or protozoan pathogens
  • - Current or past history of malignancy (including gastrointestinal cancer or polyposis)
  • - Acute substance abuse (including tobacco, >7 standard alcoholic units/week, recreational drugs)
  • - Use of probiotics or antibiotics in the past 6 months
  • - Atopic diseases (e.g. asthma, eczema)
  • - Chronic pain or chronic fatigue syndromes
  • - Overseas travel in previous three months
  • - Metabolic syndrome
  • - First-degree relative with type 2 diabetes mellitus
  • Patient exclusion criteria
  • - Bowel complications (including abscess, phlegmon, stricture, obstruction, perforation, fistula, or infection)
  • - Requiring or expected to require surgery
  • - Major abdominal surgery in the past 3 months
  • - Use of antibiotics or probiotics in the past 3 months
  • - Acute substance abuse (including tobacco, >7 standard alcoholic units/week, recreational drugs)
  • - Chronic hepatitis B, C, or HIV infection
  • - Diabetes mellitus, cancer, or systemic lupus
  • - Food allergies
  • - Allergy to Biscodyl tablets or Glycoprep
  • - Swallowing dysfunction or esophageal dysmotility

研究者

发起方
Associate Professor Justin O'Sullivan

相似试验